March 7, 2014 11:22 AM | 1 min read
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
On Friday, Barclays upgraded shares of Teva Pharmaceuticals (NASDAQ: TEVA) from Equalweight to Overweight and raised the price target from $42 to $65. Analyst Douglas Tsao's upgrade was based on the expectation “shares will experience a re-rating as the company "unlocks" value in its core generics business, deploys capital and,perhaps most importantly in the near term, manages the decline of the Copaxonefranchise through conversion to the 40mg formulation.”Tsao takes a contrarian stance to market skepticism and believes Teva will “be able to manage the decline of its Capaxone franchise in line with management's expectations through conversion to the 3x weekly mg formulation.”The analyst's research suggests “managed care will approach conversion to a potential AB-rated generic cautiously given the molecule's complexity.”Share of Teva are up 1.8 percent to $49.87 following the upgrade. Tsao's sees an additional 30 percent of upside from current levels.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.